Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

488.90INR
26 May 2017
Change (% chg)

Rs-15.10 (-3.00%)
Prev Close
Rs504.00
Open
Rs483.00
Day's High
Rs504.75
Day's Low
Rs480.20
Volume
7,010,307
Avg. Vol
1,266,963
52-wk High
Rs621.25
52-wk Low
Rs459.00

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.49
Market Cap(Mil.): Rs447,911.00
Shares Outstanding(Mil.): 804.51
Dividend: 2.00
Yield (%): 0.36

Financials

  CIPL.NS Industry Sector
P/E (TTM): 45.04 29.41 30.38
EPS (TTM): 12.36 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BUZZ-India's Cipla plunges to 11-mth low on unexpected Q4 loss

** Cipla Ltd drops as much as 4.7 pct to 480.2 rupees, its lowest since June 27, 2016

26 May 2017

Cipla lowers bio drugs investment, sharpens focus on respiratory

MUMBAI Cipla Ltd , India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday.

26 May 2017

UPDATE 1-India's Cipla lowers bio drugs investment, sharpens focus on respiratory

* Posts Q4 loss vs. analysts' forecast for profit (Recasts with CEO's comments)

26 May 2017

Indian drugmaker Cipla narrows loss in Jan-March, misses forecasts

MUMBAI, May 25 Cipla Ltd, India's fifth-largest drugmaker by sales, reported a smaller quarterly loss for January-March, but missed expectations of a profit for the period.

25 May 2017

BRIEF-India's Cipla March-qtr loss narrows

* Consol march quarter total income from operations 35.82 billion rupees

25 May 2017

BUZZ-India's Cipla hits 3-1/2-month low, technicals signal further downside

** Drug maker Cipla Ltd falls as much as 1.98 pct to 562.7 rupees, to its lowest since Jan 3

21 Apr 2017

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

06 Apr 2017

BRIEF-Medrx signs drug development and sale contract with Cipla USA Inc

* Says the company enters into a license contract with an India-based pharma Cipla Ltd's wholly owned US-based unit Cipla USA Inc, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis

06 Apr 2017

BRIEF-Cipla launches Hepatitis B vaccine in India

* Says Cipla launches Hepatitis B vaccine in India Source text - (http://bit.ly/2lUwkV6) Further company coverage:

17 Feb 2017

Cipla looks to boost US business as third-quarter profit beats estimates

MUMBAI Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market.

08 Feb 2017

More From Around the Web

Earnings vs. Estimates